JP4683727B2 - 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法 - Google Patents

線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法 Download PDF

Info

Publication number
JP4683727B2
JP4683727B2 JP2000602796A JP2000602796A JP4683727B2 JP 4683727 B2 JP4683727 B2 JP 4683727B2 JP 2000602796 A JP2000602796 A JP 2000602796A JP 2000602796 A JP2000602796 A JP 2000602796A JP 4683727 B2 JP4683727 B2 JP 4683727B2
Authority
JP
Japan
Prior art keywords
adenovirus
cells
fiber
cell
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000602796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002537816A (ja
JP2002537816A5 (enExample
Inventor
フォヘルス、ロナルト
ヨハン スホウテン、ホフェルト
ボウト、アブラハム
ヤンス エムコ ハーフェンハ、メンゾ
Original Assignee
クルーセル ホランド ベスローテン フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クルーセル ホランド ベスローテン フェンノートシャップ filed Critical クルーセル ホランド ベスローテン フェンノートシャップ
Publication of JP2002537816A publication Critical patent/JP2002537816A/ja
Publication of JP2002537816A5 publication Critical patent/JP2002537816A5/ja
Application granted granted Critical
Publication of JP4683727B2 publication Critical patent/JP4683727B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2000602796A 1999-03-04 2000-03-03 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法 Expired - Fee Related JP4683727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99200624.7 1999-03-04
EP99200624 1999-03-04
PCT/NL2000/000133 WO2000052186A1 (en) 1999-03-04 2000-03-03 Means and methods for fibroblast-like or macrophage-like cell transduction

Publications (3)

Publication Number Publication Date
JP2002537816A JP2002537816A (ja) 2002-11-12
JP2002537816A5 JP2002537816A5 (enExample) 2011-02-24
JP4683727B2 true JP4683727B2 (ja) 2011-05-18

Family

ID=8239945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000602796A Expired - Fee Related JP4683727B2 (ja) 1999-03-04 2000-03-03 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法

Country Status (7)

Country Link
EP (1) EP1159438B1 (enExample)
JP (1) JP4683727B2 (enExample)
AT (1) ATE403006T1 (enExample)
AU (1) AU776067B2 (enExample)
CA (1) CA2364499C (enExample)
DE (1) DE60039683D1 (enExample)
WO (1) WO2000052186A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
DK1681353T3 (da) * 1999-05-17 2010-01-04 Crucell Holland Bv Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (en) * 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
WO2002012523A2 (en) * 2000-08-10 2002-02-14 Crucell Holland B.V. Transduction of chondrocytes using adenoviral vectors
EP1322774A2 (en) * 2000-09-20 2003-07-02 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for dendritic cells
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
EP1195440A1 (en) * 2000-10-06 2002-04-10 Introgene B.V. Gene delivery vectors for stem cells
AU2002211087A1 (en) * 2000-10-06 2002-04-15 Crucell Holland B.V. Gene delivery vectors for stem cells
EP1279738A1 (en) * 2001-07-06 2003-01-29 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
JP4495588B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 安定なアデノウイルスベクターおよびその増殖方法
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
AU2003298361B2 (en) 2002-12-17 2009-05-14 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
AU2016333996B2 (en) 2015-10-05 2020-05-28 Salk Institute For Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
NZ759833A (en) 2017-05-26 2023-01-27 Epicentrx Inc Recombinant adenoviruses carrying transgenes
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
DE69638058D1 (de) * 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
NZ323834A (en) * 1995-11-28 2000-01-28 Genvec Inc Chimeric adenovirus coat protein vectors and methods for gene transfer to cells
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1020529B1 (en) * 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells

Also Published As

Publication number Publication date
ATE403006T1 (de) 2008-08-15
JP2002537816A (ja) 2002-11-12
EP1159438A1 (en) 2001-12-05
AU2948800A (en) 2000-09-21
CA2364499C (en) 2008-12-23
AU776067B2 (en) 2004-08-26
EP1159438B1 (en) 2008-07-30
DE60039683D1 (de) 2008-09-11
CA2364499A1 (en) 2000-09-08
WO2000052186A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
JP4683727B2 (ja) 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法
US7968087B2 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU2002315947B2 (en) Adenoviral vectors with cell type specificity for mesenchymal cells
AU2002315947A1 (en) Adenoviral vectors with cell type specificity for mesenchymal cells
US6869936B1 (en) Means and methods for fibroblast-like or macrophage-like cell transduction
JP4683682B2 (ja) 平滑筋細胞および／または内皮細胞への組織向性を与えられた遺伝子送達ベクター
EP1020529B1 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20060104953A1 (en) Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
EP1191104A1 (en) Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine
EP1191105A1 (en) Gene delivery vectors provided with a tissue tropism for T-lymphocytes
EP1279738A1 (en) Gene delivery vectors with cell type specificity for mesenchymal stem cells
NZ527635A (en) Means and methods for synoviocyte cell transduction
EP1195440A1 (en) Gene delivery vectors for stem cells
US20040043489A1 (en) Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100324

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20101102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110208

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees